Phase 4 Completed N=152 Treatment

A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

Type 2 Diabetes · Type 2 Diabetes Mellitus

Source: ClinicalTrials.gov NCT05706506 ↗

Enrolled (actual)

152

Serious AEs

0.7%

Results posted

Dec 2024

Primary outcomePrimary: Change From Baseline in Hemoglobin A1c (HbA1c) — -0.43 Percentage of HbA1c

◆ Published Evidence

No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

The main purpose of this study is to investigate the effects of switching from glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy to tirzepatide glucose-dependent insulinotropic polypeptide (GIP) GLP-1 RA agonist in participants with type 2 diabetes (T2D).

Outcome Measures

Outcome	Result	p-value
PRIMARY Change From Baseline in Hemoglobin A1c (HbA1c)	-0.43	—
SECONDARY Change From Baseline in Percentage of Time Per Day That Continuous Glucose Monitoring (CGM)-Derived Values Were >180 Milligram/Deciliter (mg/dl) (10 Millimole/Liter (mmol/L))	-6.52	—
SECONDARY Change From Baseline in Percentage of Time Per Day That CGM-derived Values Were >180 mg/dl (10 mmol/L)	-7.37	—
SECONDARY Change From Baseline in Duration of Time in Minutes Per Day That CGM Derived Values Were >180 mg/dl (10 mmol/L)	-106.09	—
SECONDARY Change From Baseline in Fasting Serum Glucose (FSG)	-7.83	—
SECONDARY Change From Baseline in Weight	-2.15	—

Eligibility Criteria

Inclusion Criteria

Have Type 2 diabetes (T2D)
Have an HbA1c c ≥6.5% (≥48 mmol/mol) to ≤9.0% (≤75 mmol/mol)
Have a body mass index (BMI) ≥25 kilogram per square meter (kg/m²) at screening
Have been on a stable treatment dose of 1 of the listed GLP-1 RAs for ≥3 months
No treatment with oral antidiabetic medicine (OAM) or on stable doses (for at least 3 months before screening) of up to 3 OAM. The OAM may include metformin, sodium-glucose linked transporter-2 inhibitor (SGLT-2i), thiazolidinediones, or α-glucosidase inhibitors.

Exclusion Criteria

Have Type 1 Diabetes (T1D)
Have a clinical history of
proliferative diabetic retinopathy
diabetic maculopathy, or
non-proliferative diabetic retinopathy that requires acute treatment
Are at high risk for cardiovascular disease or have a history of
myocardial infarction
percutaneous coronary revascularization procedure
carotid stenting or surgical revascularization
nontraumatic amputation
peripheral vascular procedure
cerebrovascular accident
or hospitalization for congestive heart failure
Have New York Heart Association (NYHA) Functional Classification Class IV congestive heart failure
Have a history of ketoacidosis or hyperosmolar state or coma
Have a history of severe hypoglycemia or hypoglycemia unawareness within the 6 months.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05706506). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.